Tossing out the inhaler may not always be the best response to outgrowing asthma, new research suggests.
Toss out the inhaler if you outgrow asthma? Not so fast
Search Results
Colonoscopy repeats greater with non-specialists
Older adults who have a colonoscopy performed by a family doctor, internist or general surgeon are somewhat more likely to need another one within a year compared with those who have the procedure done by a gastroenterologist, a new report finds.
Antidepressant patch doesn't help smokers quit
An antidepressant drug delivered through a patch on the skin is no better than placebo for helping smokers kick the habit, new research shows.
NASA advises Chile on trapped, isolated miners
A team of NASA doctors and engineers recommended Friday that Chilean authorities regulate the day-and-night sleep patterns of 33 trapped miners, boost their Vitamin D intake and phase in an exercise program as their nutrition improves.
Timer may help kids' bladder control problems
Wearing a programmable wristwatch could help children manage their daytime bladder control problems, a new study suggests.
Biotech salmon safe for eating: FDA
A biotechnology company's genetically engineered salmon are as safe to eat as other Atlantic salmon, U.S. regulators said as they weighed approval of the first DNA-altered animal for Americans' dinner plates.
Unvaccinated Teen's Life Forever Changed
FRIDAY, Sept. 3 (HealthDay News) -- Carl Buher came home from the
football game feeling rotten.
Disease May Be Only a Plane Ride Away
FRIDAY, September 3 (HealthDay News) -- A 7-year-old San Diego
boy brought back more than souvenirs and memories from a family trip to
Switzerland a couple years ago.
Health Highlights: Sept. 3, 2010
Here are some of the latest health and medical news developments,
compiled by the editors of HealthDay:
Early day care may promote eczema development
Kids who spend their earliest years in day care may be at higher risk of eczema than kids cared for at home, according to a new study from Germany.
Sanofi ready to raise bid if Genzyme talks: report
French drugmaker Sanofi-Aventis would be prepared to moderately raise its $69 per share offer for Genzyme if the U.S. biotech agreed to negotiate, Dow Jones reported, citing a person familiar with the matter.
Post new comment